Dr. Ai on the Efficacy of Brentuximab Vedotin in Patients With Advanced Cutaneous T-Cell Lymphoma

4 意见
administrator
administrator
08/09/23

Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, discusses the scenarios in which she has seen the most benefit from brentuximab vedotin (Adcetris) in patients with advanced stage cutaneous T-cell lymphoma (CTCL).

  • 类别

显示更多

0 注释 排序方式

没有找到评论

脸书评论

下一个